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Abstract
Objectives: To assess whether neurofilament light chain (NfL) could serve as
an informative endpoint in Phase 2 studies in patients with relapsing–remitting
multiple sclerosis (RRMS) and estimate the sample size requirements with NfL
as the primary endpoint. Methods: Using data from the Phase 3 FREEDOMS
study, we evaluated correlation of NfL at Month 6 with 2-year outcomes:
relapses, confirmed disability worsening (CDW), new or enlarging T2 lesions
(active lesions), and brain volume loss (BVL). We compared the proportion of
treatment effect (PTE) on 2-year relapses and BVL explained by 6-month log-
transformed NfL levels with the PTE explained by the number of active lesions
over 6 months. We estimated sample size requirements for different treatment
effects. Results: At Month 6, blood NfL levels (pg/mL, median [range]) were
lower in the fingolimod arm (fingolimod (n = 132) 18 [8–247]; placebo
(n = 114) 26 [8–159], P < 0.001). NfL at 6 months correlated with number of
relapses (r = 0.25, P < 0.001), 6-month CDW (hazard ratio 1.83, P = 0.012),
active lesions (r = 0.46, P < 0.001), and BVL (r = 0.41, P < 0.001) at Month-
24. The PTE (95% CI) on 24-month relapses and BVL explained by 6-month
NfL was 25% (8–60%) and 60% (32–132%), and by 6-month active lesions was
28% (11–66%) and 45% (18–115%), respectively. Assuming a 20–40% treat-
ment-related reduction in NfL levels, 143-28 patients per arm will be required.
Conclusions: Blood NfL may qualify as an informative and easy-to-measure
endpoint for future Phase 2 clinical studies that captures both inflammatory-
and noninflammatory-driven neuroaxonal injury in RRMS.
Introduction
In the development of treatments for multiple sclerosis
(MS) magnetic resonance imaging (MRI) measures of
inflammatory activity have played a central role as highly
predictive endpoints of proof of concept Phase 2 clinical
trials. Treatment effects on these MRI measures have been
highly predictive of effects on relapses in larger pivotal
Phase 3 trials.1,2 However, the relationship between con-
ventional MRI measures (new or enlarged T1- and T2-
weighted and contrast-enhanced T1-weighted lesions) and
neuroaxonal damage, a major determinant of permanent
disability in MS,3 is not clearly defined or fully supported
by clinical experience. Repeated cranial MRI examinations
do not cover the spinal cord, increase costs in clinical tri-
als and may become burdensome to patients as most
Phase 2 clinical trials in MS require monthly MRI scan-
ning. Several candidate laboratory markers studied in MS
lack relation to important disease processes, such as neu-
roaxonal damage, or prognostic value for important out-
comes, such as long-term disability.4 Neurofilament light
chains (NfL) have gained attention among different
potential markers because of their specificity for neuroax-
onal damage and being measurable both in CSF and
peripheral blood.5–8 With the recent development of Sin-
gle Molecule Array (SIMOA) immunoassays, NfL levels in
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blood can be reliably assessed in the full range of possible
concentrations and have shown high correlation with CSF
NfL levels9,10 and with clinical and MRI-related out-
comes.9–16
Our study aimed to assess whether NfL could serve as
a valid and informative endpoint in Phase 2 clinical trials
in relapsing–remitting MS (RRMS), in conjunction with
or as an alternative to MRI-based outcomes, and to esti-
mate the sample size requirements for a Phase 2 study
with NfL as the primary endpoint.
Methods
Patients and study design
This is a post hoc analysis of data from the placebo-con-
trolled FREEDOMS study. The study design and inclu-
sion/exclusion criteria of the FREEDOMS trial have been
previously described.17 Briefly, FREEDOMS included
patients with RRMS (diagnosed according to the 2005
revised McDonald criteria18) aged 18–55 years who had a
score of 0–5.5 on the Expanded Disability Status Scale
(EDSS) and ≥ 1 documented relapses in the previous year
or ≥ 2 relapses in the previous 2 years. Patients were ran-
domized (1:1:1) to receive fingolimod 0.5 or 1.25 mg/day
or placebo for 2 years.17 Serum NfL levels were measured
in a subset of 246 patients enrolled in the FREEDOMS
study who had at least two measurements of NfL (at
baseline and Month 6; fingolimod 0.5 mg, n = 132; pla-
cebo, n = 114).
Assessments
In the FREEDOMS study, standardized neurological
assessments, including determination of EDSS score19,
were conducted at baseline and every 3 months by neu-
rologists blinded to randomization and not further
involved in patient care. MRI scans were obtained at
baseline and Months 6, 12, and 24, or at the end of the
study for patients discontinuing prematurely.17
Relapses had to be verified by the examining neurologist
within 7 days after the onset of symptoms according to
defined criteria.17 MRI lesion activity and brain volume
loss (BVL) were assessed by a central reading site (Medical
Image Analysis Center, Basel, Switzerland) that remained
blinded for clinical data and randomization. MRI protocols
and analysis methods have been detailed elsewhere.17
The percentage brain volume change (PBVC) was
assessed using Structural Image Evaluation using Normal-
ization of Atrophy (SIENA).20 Disability worsening was
defined as an increase in the EDSS score by ≥ 1 point
sustained for ≥ 6 months (or ≥ 1.5 points if baseline
EDSS = 0).
Blood samples were collected from consented patients
at baseline and Months 6, 12, 18, and 24. NfL measure-
ments were not available for all patients who participated
in the FREEDOMS study, as not all patients consented
for the biomarker analysis, which required a separate con-
sent. Our analysis included only a subset of patients from
the FREEDOMS study with the selection criteria being
availability of NfL measurements for both baseline and
Month 6 (N = 246) to replicate the time-points for a
Phase 2 trial. There was no adjustment done for missing
data. All available blood samples were analyzed in a
blinded manner; clinical data and treatment allocation
were not disclosed to the laboratory personnel. The con-
centration of NfL in plasma samples treated with
ethylenediaminetetraacetic acid were measured by an in-
house SIMOA immunoassay.10
Statistical analysis
NfL measurements: For our study, data were analyzed in
the intent-to-treat population, defined as all individuals
with NfL values available at baseline and Month 6
(n = 246). NfL levels were log-transformed to normalize
their skewed distribution.
The primary aim of this study was to assess the validity
of NfL as a biomarker to be used as a primary endpoint
in Phase 2 trials. With this aim, we assessed the following
properties of blood NfL as measured at Month 6:
1 Do NfL levels allow detection of a treatment effect at
Month 6? For this assessment, a repeated measures
Analysis of Variance was run, with log-transformed
NfL levels at baseline and Month 6 as the dependent
variables and treatment arm as the independent vari-
able. The significance of the treatment by time interac-
tion coefficient in the model was used to assess
whether patients treated with fingolimod had a higher
reduction of NfL levels compared to the placebo arm.
2 Do 6-month NfL levels correlate with established longer
term (24 months) disease-related endpoints (number of
new or enlarged T2 lesions [active lesions], PBVC, num-
ber of relapses over 2 years and risk of 6-month con-
firmed disability worsening, CDW): These correlations
were compared to those between active lesions at
6 months (the standard Phase 2 endpoint in MS clini-
cal trials) and the same disease endpoints at
24 months. Correlations of 6-month measures (NfL
and active T2 lesions) with 24-month active lesions,
PBVC, and number of relapses were assessed by the
nonparametric Spearman coefficient. The association of
the risk of 6-month CDW with 6-month measures
(NfL and active lesions) was assessed by a Cox model
with the independent covariates included in the model
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as continuous variables and displayed by Kaplan–Meier
survival curves with the independent covariates as bin-
ary variables (comparing those with 6-month
NfL ≤ 30 pg/mL vs. those with 6-month NfL > 30 pg/
mL, and those with 6-month active lesions = 0 vs.
those with 6-month active lesions > 0). The NfL cut-
off level of 30 pg/mL is close to the geometric mean
observed in RRMS patients.21–24 The multivariate mod-
els for assessing the simultaneous impact of NfL and
active T2 lesions at 6 months were a generalized Pois-
son model for 24-month relapses, an ANOVA model
for 24-month PBVC and a Cox model for 6-month
CDW.
3 What is the contribution of NfL and active lesions as sur-
rogate markers to the treatment effect on other disease
endpoints: For a quantitative assessment of this contri-
bution, an additional measure - the proportion of
treatment effect (PTE) on Month 24 relapses, PBVC,
and disability worsening that could be attributed to the
effects on NfL and active lesions at Month 6 was calcu-
lated according to Lin, Fleming and De Gruttola
(Table S1).25 For a perfect surrogate marker, the PTE
would be 100%, indicating that the marker mediates
the full effect of the treatment; a PTE equal to 0%
would reflect the absence of surrogacy.
Finally, we estimated the sample size needed for a
Phase 2 study based on an evaluation of 6-month log-
transformed NfL concentrations, assuming different treat-
ment effect sizes.
Data availability
The current analysis included data from patients who had
provided blood samples during a Phase 3 clinical trial
(FREEDOMS). Any data not provided in the article,
including statistical analyses, assumptions and de-identi-
fied NfL levels may be shared at the request of other
investigators.
Results
Baseline characteristics of the 246 patients included in this
study are shown in Table 1 and are well comparable to
the whole FREEDOMS population,17 with no significant
differences detected. At baseline, the mean (SD) NfL
levels was 39.0 (43.8) pg/mL in the placebo and 40.0
(46.7) pg/mL in the fingolimod arm. After 6 months,
mean (SD) NfL levels were 31.9 (23.8) pg/mL in the pla-
cebo and 23.1 (23.6) pg/mL in the fingolimod arm
(Fig. 1, values on a log-scale). The median percentage
decrease in NfL levels in the fingolimod arm (33.5%)
was significantly higher than the decrease in NfL in the
placebo arm (5.4%, P < 0.001).
The 6-month NfL level was associated with the following
disease variables at Month 24 (Table 2 and Fig. 2): number
of relapses (r = 0.25, P < 0.001), cumulative risk of 6-
month CDW (hazard ratio [HR] = 1.83, P = 0.012; the
HR indicating the increase in risk of CDW for 10 pg/mL
increase in NfL at Month 6; HR = 2.08, P = 0.023 when
comparing patients with 6-month NfL higher or lower than
30 pg/mL), cumulative number of active lesions (r = 0.46,
P < 0.001), and PBVC (r = 0.41, P < 0.001). Similar cor-
relation levels were observed between 6-month active
lesions and number of relapses (r = 0.23, P < 0.001),
cumulative risk of 6-month CDW (HR = 1.03, P = 0.012;
HR indicating the increase in hazard of CDW for each
additional active lesions on the 6-month scan) and PBVC
(r = 0.30, P < 0.001) at Month 24. Only the correlation
with 24-month active lesions was higher for 6-month active
lesions (r = 0.78, P < 0.001) than for 6-month NfL. Inter-
estingly, changes in NfL levels (both absolute and percent-
age) were, at best, very weakly associated with all disease
activity endpoints at Month 24 (Table 2). In the three sepa-
rate multivariate models testing simultaneous impact of
NfL and active T2 lesions at 6 months on relapses, PBVC,
and disability worsening at Month 24 (as the dependent
variables), respectively, NfL appeared to be a better predic-
tor for these outcomes than active lesions (Table 3).
The PTE (95% CI) on 24-month relapses explained by
6-month NfL was 25% (8–60%); 6-month active lesions
explained the same PTE on relapses (28%, 11–66%). The
PTE on 24-month PBVC explained by 6-month NfL was
60% (32–132%), while the PTE on PBVC explained by 6-
month active T2 lesions was 45% (18–115%). The PTE
explained by active lesions and NfL at Month 6 on the
risk of disability worsening over 2 years was 16% (0–
56%) and 8% (0–32%), respectively.
Table 4 reports the estimated sample sizes for a Phase
2 clinical trial with blood NfL as the primary endpoint
measured at baseline and Month 6 based on different
assumptions about the treatment effect. For a standard
Phase 2 study, with 90% power and a 5% significance
level, 38 patients per arm would be needed to detect a
reduction of NfL levels by 35% at 6 months (the percent-
age obtained for fingolimod vs. placebo in our study was
33.5%). For a treatment effect of 30% or lower, the esti-
mated sample sizes range from 54 to 143 patients per
arm, e.g., close to the typical sample sizes of Phase 2 trials
in RRMS with MRI lesions as the primary endpoint.
Discussion
In this study, our focus was to assess the potential of
blood NfL as a primary endpoint in Phase 2 clinical trials
in RRMS, extrapolating from blood NfL measurements
and clinical and MRI data obtained in FREEDOMS17, a
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2-year placebo-controlled Phase 3 trial of fingolimod in
patients with RRMS. Phase 2 studies are key to the devel-
opment of new drugs and need outcomes that allow
detection of a treatment effect in a short time and on a
small number of subjects. Therefore, primary outcomes of
Phase 2 studies must be sensitive to change but also
Table 1. Baseline characteristics*.
Baseline variables
NfL subset FREEDOMS study
Placebo Fingolimod Placebo Fingolimod
N 114 132 418 425
Age, years, mean (range) 38 (19–54) 37 (19–54) 37 (18–55) 37 (18–55)
EDSS score, median (range) 2 (0–5.5) 2.25 (0–5.5) 2 (0–5.5) 2 (0–5.5)
Duration of disease, years, median (range) 7.0 (0.4–23) 6.7 (0.5–29.2) 7.0 (0–32) 6.6 (0–35)
Sex, female, % 75 69 71 70
T2LV, mm3, median (range) 3237 (0–32011) 3303 (34–43750) 3416 (0–37148) 3303 (0–47148)
NBV, cm3, mean (SD) 1504 (85) 1524 (82) 1512 (85) 1521 (83)
NfL, pg/mL
Mean (SD) 39.0 (43.8) 40.0 (46.7)
Median (range) 25.9 (8.6–379.8) 27.7 (8.4–419.4)
EDSS, Expanded Disability Status Scale; NBV, normalized brain volume; NfL, neurofilament light chain; SD, standard deviation; T2LV, T2 lesion vol-
ume.
*No significant differences in any of the baseline characteristics were detected between the group of patients who had NfL assessed versus the















Figure 1. Mean NfL levels (log-transformed) at baseline and Month 6 in patients treated with placebo (blue) and fingolimod (orange). NfL,
neurofilament light chain.
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reliable and meaningful e.g., related to and predictive of
other established and clinically relevant outcomes.
Our post hoc analysis provides several lines of evidence
that blood NfL measurements compare favorably with
established MRI-based outcomes of phase 2 studies in
relapsing MS: blood NfL levels at 6 months were sensitive
to treatment effects showing significantly lower levels in
those treated with fingolimod; blood NfL at Month 6 cor-
related with other established clinical and MRI-based out-
comes cross-sectional and – more importantly –
independently predicted these clinical and MRI-based
outcomes at month 24, and mediated part of the net
effect of the treatment on the relevant clinical endpoints.
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Figure 2. Spearman Correlations of 6-month log-transformed NfL levels with 24-month disease outcomes: Number of new or enlarging T2
lesions at Month 24 (A), number of relapses experienced over 24 months (B), Percent Brain Volume Change over 24 months (C) and the risk of
6-month confirmed disability worsening (D). HR, hazard ratio; NfL, neurofilament light chain; PBVC, percentage brain volume change; r,
correlation coefficient. The HR reported in the figure refers to the Cox model run with neurofilament light chain included as a binary variable as
explained in the legend.
Table 2. Spearman correlations of NfL levels (and change from baseline) and number of active T2 lesions at month 6 with 24-month new or
enlarging T2 lesions, PBVC and relapses.
6-month variables
24-month variablesr (P value)
New or enlarging T2 lesions Percent brain volume change Number of relapses
NfL 0.46 (<0.001) 0.41 (<0.001) 0.25 (<0.001)
NfL absolute change 0.08 (0.25) 0.16 (0.02) 0.04 (0.52)
NfL percentage change 0.13 (0.05) 0.09 (0.22) 0.00 (0.99)
Active T2 lesions 0.78 (<0.001) 0.30 (<0.001) 0.23 (<0.001)
NfL, neurofilament light chain; PBVC, percentage brain volume change; r, correlation coefficient.
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qualifies as a good biomarker to be used as a primary
endpoint in phase 2 trials.
In our study, we found no or weaker correlations of NfL
changes (absolute and/or percentage) at 6 months with 24-
month outcomes. There are contradictory reports on the
association of changes in NfL with disease outcome. In a
randomized controlled study, Kuhle et al. found that over
24 months, changes in NfL levels positively correlated with
changes in EDSS score and enhancing lesions, but not with
brain atrophy or T2 lesion volume.11 Blood NfL levels also
did not correlate with disease duration.10,24 A clear under-
standing of NfL homeostasis and clearing mechanisms and
how NfL levels in blood relate to the progressive changes in
MS disease pathology does not exist.
However, a number of studies have shown that blood
NfL levels are significantly higher in patients with MS and
were reduced after treatment with fingolimod,26 natal-
izumab27, and rituximab28 in CSF but also in several obser-
vational studies in the blood.10,12,14,16 NfL levels at baseline
correlate with clinical (such as a recent relapse and an EDSS
score) as well as MRI-related measures (such as T2 lesion
volume and number of gadolinium-enhancing lesions and
brain volume loss).10,29 High NfL levels in blood were also
associated with higher risk of future relapses and EDSS
worsening.10,16 Blood NfL levels predicted disability wors-
ening after up to 8 years and lesion load and atrophy after
10 years in patients with MS.29,30 Notably, NfL predicted
future brain and spinal cord atrophy.13,16 The PTE mea-
sures provide a quantitative description of the level of sur-
rogacy. Our results show that NfL is a suitable surrogate for
the clinical and MRI outcomes and not inferior to MRI
lesions as a surrogate of these outcomes. NfL levels in blood
tended to be better predictors of effects on BVL than active
lesions in our study. This finding is particularly important
as BVL is a comprehensive marker of both focal and diffuse
damage and is predictive of future disability worsening and
disease progression on the group level.
The findings from our study have additional relevance.
Up to now, phase 2 clinical studies have used imaging end-
points that relates to acute disease activity (such as
Gd + lesions and relapses) to assess the effect of candidate
treatments within the study duration. These MRI lesion-
based endpoints have shown a correlation with relapses in
both short-term (6–9 months, typical duration of Phase 2
trials) and mid- to long-term (12–24 months, typical dura-
tion of Phase 3 trials) follow-up durations and relate only
indirectly to disability worsening. The experimental setting
Table 3. Multivariate models for assessing the predictive value of 6-month measures (neurofilament light chain and new or enlarging T2 lesions)
on 24 month outcomes.
Effect of 6 month-NfL and new or enlarging T2 lesions on 24-month relapses (Poisson model)
Variable Unit of measure Relative risk 95% confidence interval P value
NfL Log scale 1.75 1.36 2.26 <0.001
T2 active lesions Number 1.01 0.99 1.02 0.31
Effect of 6-month NfL and new or enlarging T2 lesions on 24 month-PBVC (ANOVA model)
Variable Unit of measure beta 95% confidence interval P value
NfL Log scale 1.09 1.41 0.76 <0.001
T2 active lesions Number 0.01 0.04 0.14 0.38
Effect of 6 month-NfL and active T2 lesions on 24-month disability worsening confirmed at 6 months (Cox model)
Variable Unit of measure Hazard ratio 95% confidence interval P value
NfL Log scale 1.64 0.98 2.75 0.06
T2 active lesions Number 1.02 0.99 1.04 0.21
ANOVA, Analysis of variance; NfL, neurofilament light chain; PBVC, percentage brain volume change.
Table 4. Sample size needed for a Phase 2 clinical trial with NfL levels
measured at Month 6 as the primary endpoint (90% power, 5% sig-
nificance level).
Number of subjects per arm






NfL, neurofilament light chain.
*Treatment effect is expressed as a percentage reduction of 6-month
NfL levels in the experimental versus control arm.
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of our study is a simulation of Phase 2 trial, based on data
from a Phase 3 trial. This allowed us to test endpoints that
are more relevant to long-term disability outcomes such as,
6-month CDW and brain volume loss (BVL). Therefore,
our study provides evidence for a new phase 2 paradigm
with endpoints that relate more closely to disability not
only within the 6 months of study period but provides use-
ful prognostic information beyond the study duration.
Monitoring MRI lesions is useful in clinical practice to
determine disease activity, but they provide retrospective
aspects of the disease. Also, it is not feasible to repeat cra-
nial MRI scans and even more difficult spinal MRI scans
frequently in routine practice because of the complexity
and cost. The temporal association with active disease and
the corresponding clinical manifestation is therefore fre-
quently lacking. Measurement of NfL in blood is minimally
invasive, can be done at high frequency, is less burdensome
to patients, and correlates well with relevant clinical out-
comes in RRMS. Therefore, NfL levels are a promising bio-
marker candidate to be used in future short-term proof of
concept studies in relapsing MS. Future studies will investi-
gate their potential to facilitate and inform trials in pro-
gressive MS.
The post hoc nature of this analysis is a limitation of the
study but the setting of a large Phase 3 trial provides the
opportunity to evaluate the prognostic qualities of NfL in a
well-characterized sample of typical relapsing MS patients.
However, our results may not be generalizable to other MS
phenotypes or to patients in routine clinics who may pre-
sent with comorbidities and would have been otherwise
excluded from controlled clinical studies. Whether the role
of NfL as a correlate of clinical outcomes is independent,
or at least complementary, to inflammatory MRI activity
should be further investigated. Additionally, future studies
need to directly compare the added value of frequent, e.g.,
monthly NfL and imaging assessments. This would be par-
ticularly important if we take into account that measuring
NfL blood levels would be much easier and cost efficient
than frequent MRI scans.
In summary, our results show that levels of NfL in blood
measured at 6 months have the necessary properties to
qualify as an endpoint for Phase 2 studies in RRMS, with
the potential to provide comprehensive information on
neuroaxonal integrity, irrespective of its specific cause,
inflammatory or degenerative, on a trial level.
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